Publicado 04/06/2018 14:01
- Comunicado -

Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab) (3)

Contacts Merck Media Friederike Segeberg +49-6151-72-6328 Investor Relations +49-6151-72-3321 Pfizer Media (US) Jessica Smith +1-212-733-6213 Investor Relations Ryan Crowe +1-212-733-8160

(Logo: http://mma.prnewswire.com/media/611425/M... )

Photo: http://mma.prnewswire.com/media/611425/M...

Contenido patrocinado